TuHURA Biosciences, Inc.
HURAHealthcare|Biotechnology|US
$1.63
+0.02 (+1.24%)
Tangible Book / Share
$0.12
Cash / Share
$0.02
About
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Stock Price
-33.5%(1Y)
1M
-15.5%
3M
-23.5%
6M
-31.5%
YTD
+115.4%
1Y
-34.3%
3Y
-88.8%
5Y
-96.6%
Pipeline Summary
6 total trials3
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
Completed: 3Recruiting: 2Available: 1
Active Trials (2)
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928Advanced Or Metastatic Merkel Cell Carcinoma
Phase 2Phase 3Recruiting
Enrollment: 118 participants
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
NCT06940440Advanced Or Metastatic Merkel Cell Carcinoma
Phase 1Recruiting
Enrollment: 9 participants
Key Facts
Market Cap$103.9M
Employees22 (+16% YoY)
CEOJames A. Bianco
IPO DateFeb 22, 2013
Beta-0.01
52-Week Range$0.41 – $3.43
Avg Volume295,922
ExchangeNASDAQ
Websitetuhurabio.com
Ownership
Float62.3%
Shares Outstanding63.7M
Recent Insider Trades
Bianco James A.GIFT
May 28, 2026150,000 shares
Tendler CraigAWARD
Feb 12, 2026156,240 shares @ $1.29
Ng George KAWARD
Feb 12, 2026156,240 shares @ $1.29
MANUSO JAMES S JAWARD
Feb 12, 2026156,240 shares @ $1.29
List AlanAWARD
Feb 12, 2026156,240 shares @ $1.29
Peers
Recent News
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
Nov 4, 2026 · prnewswire.com
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
Oct 26, 2026 · marketbeat.com
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
Oct 26, 2026 · prnewswire.com
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
Oct 13, 2026 · prnewswire.com
Data last updated: Nov 9, 2026, 04:13 AM